Skip to main content
SpringerLink
Log in

Primary CNS Lymphoma: Treatment with Combined Chemotherapy and Radiotherapy

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Primary central nervous system lymphoma (PCNSL) is a relatively uncommon primary brain tumor, but it has become the focus of many clinical trials because of its rising incidence and unique sensitivity to systemic chemotherapeutic agents. Radiotherapy can achieve high response rates and remissions in most patients, but survival is usually only 12–18 months because disease recurs. The addition of systemic chemotherapy, particularly intravenous methotrexate, had markedly improved disease control and many patients can achieve a durable remission and occasionally cure of their disease. Conventional systemic lymphoma drug combinations such as cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) are ineffective. High-dose methotrexate is the single most active and important agent in the treatment of this disease. Whether improved disease control can be accomplished by adding other drugs to high-dose methotrexate or whether it is sufficient as a single agent has yet to be answered. High-dose methotrexate combined with cranial irradiation yields a median survival of at least 40 months and five year survival rates of 22%. However, neurotoxicity is substantial in a significant proportion of patients, particularly those over the age of 60 at the time of treatment. As many as 50% of such patients develop severe dementia. This is particularly important in a disease where approximately half of patients above the age of 60 had presentation. Efforts are now being directed towards not only improving disease control but also minimizing late neurotoxicity. Most efforts are currently directed towards using chemotherapy as the sole modality in the treatment of PCNSL, but both an optimal chemotherapy regimen, and the role of radiotherapy remain to be determined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Eby NL, Grufferman S, Flannelly CM, Schold SC Jr, Vogel F, Burger PC: Increasing incidence of primary brain lymphoma in the US. Cancer 62: 2461–2465, 1988

    PubMed  Google Scholar 

  2. DeAngelis LM: Current management of primary central nervous system lymphoma. Oncology 9: 63–78, 1995

    PubMed  Google Scholar 

  3. DeAngelis LM, Yahalom J, Thaler HT, Kher U: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10: 635–643, 1992

    PubMed  Google Scholar 

  4. Reni M, Ferreri AJM, Garancini MP, Villa E: Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 8: 227–234, 1997

    Google Scholar 

  5. Blay J-Y, Conroy T, Chevreau C, Thyss A, Quesnel, Eghbali, Bouabdallah R, Coiffier B, Wagner J-P, Le Mevel A, Dramais-Marcel D, Baumelou E, Chauvin F, Biron P: Highdose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 6: 864–871, 1998

    Google Scholar 

  6. Corry J, Smith JG, Wirth A, Quong, G, Liew KH: Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41: 615–620, 1998

    PubMed  Google Scholar 

  7. Singh A, Strobos RJ, Singh BM, Rothballer AB, Reddy V, Puljic S, Poon TP: Steroid-induced remission in CNS lymphoma. Neurology 32: 1267–1271, 1982

    PubMed  Google Scholar 

  8. Pirotte B, Levivier M, Goldman S, Brucher J-M, Brotchi J, Hildebrand J: Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and reviewof the literature. J Neuro-Oncol 32: 63–69, 1997

    Google Scholar 

  9. DeAngelis LM, Yahalom J, Heinemann M-H, Cirrincione C, Thaler HT, Krol G: Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 40: 80–86, 1990

    PubMed  Google Scholar 

  10. Bleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 65 (Suppl 11): 89–98, 1981

    Google Scholar 

  11. Geyer JR, Taylor EM, Milstein JM: Radiation, methotrexate and white matter necrosis: laboratory evidence for neural radioprotection with preirradiation methotrexate. Int J Radiat Oncol Biol Phys 15: 373–375, 1988

    PubMed  Google Scholar 

  12. Fisher RI, Gaynor ER, Dahlaberg S, OkenMM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Eng J Med 328: 1002–1006, 1993

    PubMed  Google Scholar 

  13. Lachance DH, Brizel DM, Gockerman JP, Halperin EC, Burger PC, Boyko OB, Brown MT, Schold SC: Cyclophosphamide, doxorubicin, vincristine and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 44: 1721–1727, 1994

    PubMed  Google Scholar 

  14. Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom J: Preirradiation chemotherapy with cyclophosphamide doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88–06. J Clin Oncol 14: 556–564, 1996

    PubMed  Google Scholar 

  15. O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL: Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Rad Oncol Biol Phys 33: 663–673, 1995

    Google Scholar 

  16. Brada M, Dearnaley D, Horwich A, Bloom HJG: Management of primary cerebral lymphoma with initial chemotherapy: preliminary results and comparison with patients treated with radiotherapy alone. Int J Rad Oncol Biol Phys 18: 787–792, 1990

    Google Scholar 

  17. Ott RJ, Brada M, Flower MA, Babich JW, Cherry SR, Deehan BJ: Measurements of blood-brain barrier permeability inpatients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 27: 1356–1361, 1991

    PubMed  Google Scholar 

  18. Ervin T, Canellos GP: Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer 45: 1556–1557, 1980

    PubMed  Google Scholar 

  19. Loeffler JS, Ervin TJ, Mauch P, Skarin A, Weinstein HJ, Canellos G, Cassady JR: Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. J Clin Oncol 3: 490–494, 1985

    PubMed  Google Scholar 

  20. Gabbai AA, Hochberg FH, Linggood RM, Bashir R, Hotleman K: High-dose methotrexate for non-AIDS primary central nervous system lymphoma report of 13 cases. J Neurosurg 70: 190–194, 1989

    PubMed  Google Scholar 

  21. 21.Glass J, Gruber ML, Cher L, Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81: 188–195

  22. Abrey LE, DeAngelis LM, Yahalom J: Long-term survival in primary central nervous system lymphoma. J Clin Oncol 16: 1–6, 1998

    PubMed  Google Scholar 

  23. DeAngelis LM, Delattre JY, Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 39: 789–796, 1989257

    PubMed  Google Scholar 

  24. Merchut MP, Haberland C, Naheedy MH, Rubino FA: Long survival of primary cerebral lymphoma with progressive radiation necrosis. Neurology 35: 552–556, 1985

    PubMed  Google Scholar 

  25. Chamberlain MC, Levin VA: Primary central nervous system lymphoma: a role for adjuvant chemotherapy. J Neuro-Oncol 14: 271–275, 1992

    Google Scholar 

  26. Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexatebased chemotherapy and deferred radiotherapy: preliminary results. Neurology 46: 1757–1759, 1996

    PubMed  Google Scholar 

  27. Freilich RJ, Delattre J-Y, Monjour A, DeAngelis LM: Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46: 435–439, 1996

    PubMed  Google Scholar 

  28. Dahlborg SA, Henner WD, Crossen JR, Tableman M, Petrillo A, Braziel R, Neuwelt EA: Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhances chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2: 166–174, 1996

    PubMed  Google Scholar 

  29. SandorV, Stark-VancsV, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, Patronas N, Heiss J, Jaffe E, deSmet M, Kohler D, Simon R, Wittes R: Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16: 3000–3006, 1998

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Lisa M. DeAngelis

Authors
  1. Lisa M. DeAngelis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

DeAngelis, L.M. Primary CNS Lymphoma: Treatment with Combined Chemotherapy and Radiotherapy. J Neurooncol 43, 249–257 (1999). https://doi.org/10.1023/A:1006258619757

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006258619757

Search

Navigation